Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience

Mostrar otras versiones (1)

INTRODUCTION: In November 2020, the FDA issued an emergency use authorization (EUA) for monoclonal antibody (mAb) therapy in patients with mild‐to‐moderate COVID‐19 at high risk for disease progression. METHODS: We retrospectively reviewed 38 adult hematology patients who received mAbs from 11/2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Amanam, Idoroenyi, Yao, Janny, Puing, Alfredo, Tsai, Ni‐Chun, Samuels, Diana, Ngo, Dat, Ho, Stephanie, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, Artz, Andrew, Htut, Myo, Koller, Paul, Salhotra, Amandeep, Sandhu, Karamjeet, Nikolaenko, Liana, Pawlowska, Anna, Shouse, Geoffrey, Stein, Anthony, Marcucci, Guido, Forman, Stephen, Nakamura, Ryotaro, Dadwal, Sanjeet, Al Malki, Monzr M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
BRIEF COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242327/
https://www.ncbi.nlm.nih.gov/pubmed/37081733
http://dx.doi.org/10.1002/cam4.5832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242327/
https://www.ncbi.nlm.nih.gov/pubmed/37081733
http://dx.doi.org/10.1002/cam4.5832

Ejemplares similares